Bavarian Nordic AS (BVNKF) reports a robust 62% revenue increase, driven by vaccine success and strategic government ...

Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023.

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Bavarian Nordic A/S (($BVNRY)) has held its Q1 earnings call. Read on for the main highlights of the call. Bavarian Nordic’s recent earnings call ...

Chikungunya is a mosquito-borne tropical disease that causes intense joint pain and fever. Although it is rare in the U.S., about 100 to 200 cases are reported annually, mostly among Americans ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three ...

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

Good day and thank you for standing by. Welcome to the Bavarian Nordic Q1 2025 Results, Conference Call and Webcast. At this time all participants will be in a listen-only mode. After the speaker ...

European shares extended gains on Friday, with Germany's DAX index closing at an all-time high, as signs of easing global ...

European stock markets saw gains. Germany's DAX reached a record high. Investors felt relieved by signs of a possible ease in ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...